⁶⁸Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with ¹⁷⁷Lu-PSMA-617.

ABSTRACT:

Background

Differentiated thyroid carcinoma (DTC) is the most common type of thyroid cancer. Treatment with surgery, radioactive iodine (RAI), and TSH suppression is effective in most patients. Five to 15% of patients become RAI refractory and need alternative therapy; however, treatment options are limited. ⁶⁸Ga-PSMA PET/CT, originally developed for prostate cancer, is also applicable to other malignancies, including thyroid carcinoma. The uptake of PSMA in thyroid carcinoma gives opportunities for imaging and therapy of RAI-refractory DTC. The aim of this study was to analyze imaging on ⁶⁸Ga-PSMA PET/CT and evaluate the response to ¹⁷⁷Lu-PSMA-617 therapy in patients with RAI-refractory DTC.

Materials and methods

Five patients with RAI-refra

SUBMITTER: de Vries LH 

PROVIDER: S-EPMC7060303 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature